Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an announcement.
Australian Clinical Labs Ltd has continued its on-market share buy-back program for its ordinary fully paid shares, ACL, as disclosed in an updated Appendix 3C filing. The latest daily notification dated 8 April 2026 reports that a total of 7,505,380 shares had been repurchased before the previous day, with a further 109,787 shares bought back on the previous trading day.
The ongoing buy-back, first notified in October 2025 and now subject to regular daily updates, indicates a sustained capital management strategy by the company. This program is likely aimed at optimising the company’s capital structure and may support earnings per share and shareholder value by reducing the number of shares on issue over time.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is an Australian-listed healthcare company operating in the pathology and diagnostic services sector. Its primary business involves providing laboratory testing and related clinical services, with its ordinary fully paid shares traded on the ASX under the code ACL.
Average Trading Volume: 800,946
Technical Sentiment Signal: Sell
Current Market Cap: A$383.9M
See more insights into ACL stock on TipRanks’ Stock Analysis page.